Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
30.73M | 25.88M | 21.09M | 15.91M | 15.35M | 21.42M |
Gross Profit | |||||
12.40M | 12.45M | 9.57M | 6.73M | 6.75M | 8.95M |
EBIT | |||||
1.03M | 1.37M | 1.14M | -1.41M | 335.47K | -1.79M |
EBITDA | |||||
1.90M | 2.14M | 1.76M | -772.74K | 894.88K | -1.44M |
Net Income Common Stockholders | |||||
598.75K | 929.50K | 717.96K | -1.92M | 198.13K | -1.90M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
2.82M | 6.97M | 2.81M | 2.46M | 4.24M | 4.77M |
Total Assets | |||||
13.61M | 16.79M | 13.51M | 9.60M | 11.55M | 10.44M |
Total Debt | |||||
3.34M | 3.89M | 4.73M | 5.31M | 4.81M | 3.30M |
Net Debt | |||||
521.68K | -3.07M | 1.92M | 2.84M | 572.63K | -1.48M |
Total Liabilities | |||||
9.72M | 13.37M | 11.59M | 8.55M | 8.58M | 8.44M |
Stockholders Equity | |||||
3.93M | 3.46M | 1.97M | 1.08M | 3.04M | 2.10M |
Cash Flow | Free Cash Flow | ||||
753.69K | 5.02M | 1.33M | -1.99M | -1.31M | 1.03M |
Operating Cash Flow | |||||
867.51K | 5.40M | 1.41M | -1.64M | -1.19M | 1.31M |
Investing Cash Flow | |||||
-113.83K | -376.89K | -77.70K | -351.93K | -125.39K | -280.55K |
Financing Cash Flow | |||||
-1.29M | -1.06M | -1.04M | 357.56K | 892.79K | -451.09K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $5.10B | 18.92 | 6.48% | 6.61% | 5.08% | ― | |
66 Neutral | C$15.68M | ― | -5.60% | ― | -10.37% | 95.22% | |
65 Neutral | C$534.80M | ― | -14.10% | ― | 31.68% | 67.90% | |
62 Neutral | C$20.77M | 34.29 | 17.34% | ― | 17.76% | -72.66% | |
58 Neutral | $9.12B | 5.24 | -7.59% | 7.51% | 0.53% | -65.25% |
Thermal Energy International has secured its largest engineering contract to date, valued at $500,000, with a major multinational pharmaceutical company for a potential heat recovery project. This deal marks the second significant engagement with a leading pharmaceutical company and reflects the firm’s strategic positioning in the industry. The project aligns with the pharmaceutical sector’s commitment to reducing carbon emissions, contributing to the United Nation’s Race to Zero campaign. This contract showcases Thermal Energy’s capacity to deliver extensive engineering solutions and highlights the untapped potential for large-scale heat recovery projects within the pharmaceutical industry.
Thermal Energy International Inc. reported record revenue for the second quarter ending November 30, 2024, with a 22% increase to $8.7 million. Despite lower profitability due to product mix changes and increased investments in infrastructure and staff, the company achieved significant progress in its growth strategy. Thermal Energy’s recent investments, including a larger UK production facility and new technologies, have yet to yield their full benefits, but have set the stage for future expansion. The company noted a strong order backlog and maintained positive cash flow from operations, reinforcing its financial stability and strategic growth plans.
Thermal Energy International announced that it will release its second quarter financial results for fiscal 2025 on January 28, 2025. The release will be followed by an earnings conference call and webcast, providing an opportunity for qualified equity analysts to engage in a question-and-answer session. This announcement highlights the company’s ongoing commitment to transparency and engagement with stakeholders, potentially impacting investor perceptions and market positioning.